Ethinylestradiol/levonorgestrel monophasic - Bayer Schering Pharma

Drug Profile

Ethinylestradiol/levonorgestrel monophasic - Bayer Schering Pharma

Alternative Names: Levlite; Levonorgestrel/ethinylestradiol - Berlex; Microgynon 20; Microgynon 30; Microgynon Suave; Microlevlen ED; Microlite; Miranova

Latest Information Update: 11 Feb 2015

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Class Alkylated estrogenic steroids; Contraceptives; Hormonal replacements; Norpregnanes; Norpregnatrienes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Contraception

Most Recent Events

  • 11 Feb 2015 Launched for Contraception/Pregnancy (Prevention) in United Kingdom, Austria, Belgium, Greece, Israel, Netherlands, Poland, Singapore, Finland, Czech Republic, Russia, Spain, Norway, Thailand, Indonesia, Chile, Mexico, Malaysia and Hong Kong (PO) prior to February 2015
  • 04 Apr 2007 Berlex Inc has been acquired by Bayer HealthCare (MR 9074204)
  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top